Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 2/20 | 0.37 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.35 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.35 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.35 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | STAT6 | P42226 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphine SCHEMBL25171299 | 1.00 | SLC22A2 (0.37) | SLC22A2SLC47A1MAPTGRIN2DGRIN3B | |
| SCHEMBL498011 | 1.00 | SLC22A2 (0.37) | SLC22A2SLC47A1MAPTGRIN2DGRIN3B | |
| Ammonia Solution, Strong SCHEMBL28147130 | 0.97 | SLC22A2 (0.36) | SLC22A2SLC47A1MAPTGRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL5707247 | 0.97 | MAPT (0.39) | SLC22A2SLC47A1MAPTGRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL29213093 | 0.95 | MAPT (0.38) | SLC22A2SLC47A1MAPTGRIN2DGRIN3B | |
| Formamide SCHEMBL27718948 | 0.87 | SLC22A2 (0.34) | SLC22A2SLC47A1MAPTGRIN2DGRIN3B | |
| Phosphoric Acid SCHEMBL27711128 | 0.87 | GAA (0.43) | SLC22A2SLC47A1 | |
| Formic Acid SCHEMBL28177125 | 0.87 | THRB (0.31) | SLC22A2SLC47A1THRB | |
| SCHEMBL28239328 | 0.84 | — | — | |
| Biphenyl SCHEMBL261710 | 0.82 | OPRK1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137448-A1 | Methods for Treating Neuropsychiatric Disorders with NMDA Receptor Antagonists | NEUROMOLECULAR, INC. | 2010-06-03 | — | — | US | disclosed |
| EP-1852113-A2 | Methods for treating neuropsychiatric disorders with NMDA receptors antagonists | Neuromolecular Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| EP-1351670-A4 | METHODS FOR TREATING NEUROPSYCHIATRIC DISORDERS WITH NMDA RECEPTOR ANTAGONISTS | NEUROMOLECULAR INC (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20040122090-A1 | Methods for treating neuropsychiatric disorders with nmda receptor antagonists | NEUROMOLECULAR PHARMACEUTICALS INC. | 2004-06-24 | — | — | US | disclosed |
| CN-1486180-A | Methods for treating neuropsychiatric disorders with NMDA receptor antagonists | 纽热莫勒丘乐有限公司 | 2004-03-31 | — | — | CN | disclosed |
| EP-1351670-A1 | METHODS FOR TREATING NEUROPSYCHIATRIC DISORDERS WITH NMDA RECEPTOR ANTAGONISTS | Neuromolecular Inc. (US) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002045710-A9 | METHODS FOR TREATING NEUROPSYCHIATRIC DISORDERS WITH NMDA RECEPTOR ANTAGONISTS | NEUROMOLECULAR INC (US) | 2003-04-24 | — | — | WO | disclosed |
| WO-2002045710-A1 | METHODS FOR TREATING NEUROPSYCHIATRIC DISORDERS WITH NMDA RECEPTOR ANTAGONISTS | NEUROMOLECULAR INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122090-A1 | Methods for treating neuropsychiatric disorders with nmda receptor antagonists | GRIN2A, GRIN1, GRIN3A | SLC22A2 1503/4885SLC47A1 3045/4885MAPT 374/4885 |
| US-20100137448-A1 | Methods for Treating Neuropsychiatric Disorders with NMDA Receptor Antagonists | GRIN2A, GRIN1, GRIN3A | SLC22A2 1503/4885SLC47A1 3045/4885MAPT 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.